- Home
- MediaOutReach
- Notice to Long-term Integra Lifesciences Holdings Corporation (IART) Shareholders: Grabar Law Investigates Claims on Your Behalf
Notice to Long-term Integra Lifesciences Holdings Corporation (IART) Shareholders: Grabar Law Investigates Claims on Your Behalf
Selasa, 25 Maret 2025 | 13:02
Philadelphia, Pennsylvania -
Newsfile Corp.
- March 24, 2025 - Grabar Law Office is investigating whether the Board
of Directors of Integra LifeSciences Holdings Corp. (NASDAQ: IART)
breached their fiduciary duties owed to the Company.
Current Integra LifeSciences Holdings Corp. (NASDAQ: IART)
shareholders who have held the stock since on or before March 11, 2019,
can seek corporate reforms, the return of funds spent defending
litigation back to the company, and a court approved incentive award, at
no cost to them.
Learn more or join at: https://grabarlaw.com/the-latest/intrga-lifesciences-shareholder-investigation/. Contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
WHY: An underlying securities fraud class action complaint
alleges that Integra, via certain of his officers and directors,
repeatedly touted that it was on track to grow SurgiMend's market by
obtaining FDA approval for use in post-mastectomy reconstruction, yet on
May 23, 2023, the Company was forced to announce a "recall" of all
products manufactured at its Boston Facility between March 1, 2018 and
May 22, 2023. Integra LifeSciences explained that it had determined that
the Boston Facility deviated from good manufacturing practices in
testing for bacterial endotoxin and allowed the release of products with
unsafe levels of endotoxins. As a result of the recall and
manufacturing shutdown, the Company revised its guidance for the second
quarter of 2023, lowering its revenue expectations by and disclosed that
it expected to take a $22 million impairment due to the inventory
write-off.
WHAT TO DO NOW: Current Integra LifeSciences shareholders who
have held Integra LifeSciences shares since on or before March 11, 2019,
can seek corporate reforms, the return of funds spent defending
litigation back to the company, and a court approved incentive award, at
no cost to them.
If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/intrga-lifesciences-shareholder-investigation/, contact Joshua H. Grabar at
jgrabar@grabarlaw.com, or call us at 267-507-6085. $IART #IntegraLifeSciences
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email:
jgrabar@grabarlaw.com
BERITA LAINNYA
BERIKAN KOMENTAR